Other Species / Isoforms
  HN1 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
K8-ac
MTTTTTFkGVDPNsR
0 5
HN1 (human) MTTTTTFkGVDPNsR K8-ac
HN1 iso2 (human) MTTTTTFKGVDPNSR K8
HN1 (mouse) MTTTTTFKGVDPNsR K8
HN1 (rat) MTTTTTFkGVDPNSR K8-ac
K8-ub
MTTTTTFkGVDPNsR
0 4
HN1 (human) MTTTTTFkGVDPNsR K8-ub
HN1 iso2 (human) MTTTTTFKGVDPNSR K8
HN1 (mouse) MTTTTTFKGVDPNsR K8
HN1 (rat) MTTTTTFKGVDPNSR K8
K8-m1
MTTTTTFkGVDPNsR
0 1
HN1 (human) MTTTTTFkGVDPNsR K8-m1
HN1 iso2 (human) MTTTTTFKGVDPNSR K8
HN1 (mouse) MTTTTTFKGVDPNsR K8
HN1 (rat) MTTTTTFKGVDPNSR K8
S14-p
FkGVDPNsRNsSRVL
0 2
HN1 (human) FkGVDPNsRNsSRVL S14-p
HN1 iso2 (human) FKGVDPNSRNSSRVL S14
HN1 (mouse) FKGVDPNsRNSSRVL S14-p
HN1 (rat) FkGVDPNSRNSSRVL S14
S17-p
VDPNsRNsSRVLrPP
Upstream
0 1
Treatment
  • nocodazole
HN1 (human) VDPNsRNsSRVLrPP S17-p
HN1 iso2 (human) VDPNSRNSSRVLRPP S17
HN1 (mouse) VDPNsRNSSRVLRPP S17
HN1 (rat) VDPNSRNSSRVLRPP S17
R22-m1
RNsSRVLrPPGGGsN
0 1
HN1 (human) RNsSRVLrPPGGGsN R22-m1
HN1 iso2 (human) RNSSRVLRPPGGGSN R22
HN1 (mouse) RNSSRVLRPPGGGsN R22
HN1 (rat) RNSSRVLRPPGGGSN R22
S28-p
LrPPGGGsNFsLGFD
0 18
HN1 (human) LrPPGGGsNFsLGFD S28-p
HN1 iso2 (human) LRPPGGGSNFSLGFD S28
HN1 (mouse) LRPPGGGsNFsLGFD S28-p
HN1 (rat) LRPPGGGSNFSLGFD S28
S31-p
PGGGsNFsLGFDEPT
0 22
HN1 (human) PGGGsNFsLGFDEPT S31-p
HN1 iso2 (human) PGGGSNFSLGFDEPT S31
HN1 (mouse) PGGGsNFsLGFDEPA S31-p
HN1 (rat) PGGGSNFSLGFDEPT S31
K46-ub
EQPVRKNkMAsNIFG
0 6
HN1 (human) EQPVRKNkMAsNIFG K46-ub
HN1 iso2 (human) EQPVRKNKMASNIFG K46
HN1 (mouse) EQPVRKNKMAsNIFG K46
HN1 (rat) EQPVRKNKMASNIFG K46
S49-p
VRKNkMAsNIFGtPE
0 3
HN1 (human) VRKNkMAsNIFGtPE S49-p
HN1 iso2 (human) VRKNKMASNIFGTPE S49
HN1 (mouse) VRKNKMAsNIFGtPE S49-p
HN1 (rat) VRKNKMASNIFGtPE S49
T54-p
MAsNIFGtPEENQAs
Upstream
0 67
Treatment
  • anti-CD3
  • BI_4834
  • ischemia
  • nocodazole
HN1 (human) MAsNIFGtPEENQAs T54-p
HN1 iso2 (human) MASNIFGTPEENQAS T54
HN1 (mouse) MAsNIFGtPEENPPs T54-p
HN1 (rat) MASNIFGtPEENPPS T54-p
S61-p
tPEENQAsWAkSAGA
0 6
HN1 (human) tPEENQAsWAkSAGA S61-p
HN1 iso2 (human) TPEENQASWAKSAGA S61
HN1 (mouse) tPEENPPsWAkSAGS S61-p
HN1 (rat) tPEENPPSWAKSAGG S61
K64-ub
ENQAsWAkSAGAkss
0 7
HN1 (human) ENQAsWAkSAGAkss K64-ub
HN1 iso2 (human) ENQASWAKSAGAkSS K64
HN1 (mouse) ENPPsWAkSAGSkSs K64-ub
HN1 (rat) ENPPSWAKSAGGRED K64
K69-ub
WAkSAGAkssGGRED
0 9
HN1 (human) WAkSAGAkssGGRED K69-ub
HN1 iso2 (human) WAKSAGAkSSGGRED K69-ub
HN1 (mouse) WAkSAGSkSsGGRED K69-ub
HN1 (rat) gap -
S70-p
AkSAGAkssGGREDL
0 7
HN1 (human) AkSAGAkssGGREDL S70-p
HN1 iso2 (human) AKSAGAkSSGGREDL S70
HN1 (mouse) AkSAGSkSsGGREDS S70
HN1 (rat) gap -
S71-p
kSAGAkssGGREDLE
0 10
HN1 (human) kSAGAkssGGREDLE S71-p
HN1 iso2 (human) KSAGAkSSGGREDLE S71
HN1 (mouse) kSAGSkSsGGREDSE S71-p
HN1 (rat) gap -
S79-p
GGREDLEssGLQRRN
0 30
HN1 (human) GGREDLEssGLQRRN S79-p
HN1 iso2 (human) GGREDLESSGLQRRN S79
HN1 (mouse) GGREDSEsPGTQRsN S79-p
HN1 (rat) GGREDSESPGTQRsN S74
S80-p
GREDLEssGLQRRNs
Upstream
0 55
Treatment
  • BI_4834
HN1 (human) GREDLEssGLQRRNs S80-p
HN1 iso2 (human) GREDLESSGLQRRNs S80
HN1 (mouse) GREDSEsPGTQRsNs P80
HN1 (rat) GREDSESPGTQRsNs P75
R85
EssGLQRRNssEAss
0 10
HN1 (human) EssGLQRRNssEAss R85
HN1 iso2 (human) ESSGLQRRNssEAss R85
HN1 (mouse) EsPGTQRsNssEASs S85-p
HN1 (rat) ESPGTQRsNssEASs S80-p
S87-p
sGLQRRNssEAssGD
Upstream
0 611
Regulatory protein:
  • TBK1 (human)
Treatment
  • metastatic potential
  • nocodazole
HN1 (human) sGLQRRNssEAssGD S87-p
HN1 iso2 (human) SGLQRRNssEAssGD S87-p
HN1 (mouse) PGTQRsNssEASsGD S87-p
HN1 (rat) PGTQRsNssEASsGD S82-p
S88-p
GLQRRNssEAssGDF
Upstream
0 360
Treatment
  • metastatic potential
  • nocodazole
  • U0126
HN1 (human) GLQRRNssEAssGDF S88-p
HN1 iso2 (human) GLQRRNssEAssGDF S88-p
HN1 (mouse) GTQRsNssEASsGDF S88-p
HN1 (rat) GTQRsNssEASsGDF S83-p
S91-p
RRNssEAssGDFLDL
0 26
HN1 (human) RRNssEAssGDFLDL S91-p
HN1 iso2 (human) RRNssEAssGDFLDL S91-p
HN1 (mouse) RsNssEASsGDFLDL S91
HN1 (rat) RsNssEASsGDFLDL S86
S92-p
RNssEAssGDFLDLK
0 35
HN1 (human) RNssEAssGDFLDLK S92-p
HN1 iso2 (human) RNssEAssGDFLDLK S92-p
HN1 (mouse) sNssEASsGDFLDLK S92-p
HN1 (rat) sNssEASsGDFLDLK S87-p
S115-p
VDTDLPGsLGQsEEK
0 4
HN1 (human) VDTDLPGsLGQsEEK S115-p
HN1 iso2 (human) gap -
HN1 (mouse) VDTDFQANLAQMEEK N115
HN1 (rat) VDTDFQASLAQVEEK S110
S119-p
LPGsLGQsEEKPVPA
0 2
HN1 (human) LPGsLGQsEEKPVPA S119-p
HN1 iso2 (human) gap -
HN1 (mouse) FQANLAQMEEKPVPA M119
HN1 (rat) FQASLAQVEEKPVPA V114
S131-p
VPAAPVPsPVAPAPV
Upstream
0 75
Regulatory protein:
  • PRKD1 (human)
Treatment
  • dasatinib
  • nocodazole
HN1 (human) VPAAPVPsPVAPAPV S131-p
HN1 iso2 (human) gap -
HN1 (mouse) VPAAPVPsPVAPAPV S131-p
HN1 (rat) VPAAPVPsPVAPAPA S126-p
S140-p
VAPAPVPsRRNPPGG
0 1
HN1 (human) VAPAPVPsRRNPPGG S140-p
HN1 iso2 (human) gap -
HN1 (mouse) VAPAPVPSRRNPPGG S140
HN1 (rat) VAPAPAPSRRNPPGG S135
K148-ac
RRNPPGGkssLVLG_
Upstream
0 7
Treatment
  • vorinostat
HN1 (human) RRNPPGGkssLVLG_ K148-ac
HN1 iso2 (human) gap -
HN1 (mouse) RRNPPGGKSSLVLG_ K148
HN1 (rat) RRNPPGGkSSLVLG_ K143-ac
K148-m1
RRNPPGGkssLVLG_
0 1
HN1 (human) RRNPPGGkssLVLG_ K148-m1
HN1 iso2 (human) gap -
HN1 (mouse) RRNPPGGKSSLVLG_ K148
HN1 (rat) RRNPPGGKSSLVLG_ K143
S149-p
RNPPGGkssLVLG__
0 5
HN1 (human) RNPPGGkssLVLG__ S149-p
HN1 iso2 (human) gap -
HN1 (mouse) RNPPGGKSSLVLG__ S149
HN1 (rat) RNPPGGkSSLVLG__ S144
S150-p
NPPGGkssLVLG___
0 9
HN1 (human) NPPGGkssLVLG___ S150-p
HN1 iso2 (human) gap -
HN1 (mouse) NPPGGKSSLVLG___ S150
HN1 (rat) NPPGGkSSLVLG___ S145